RU94019984A - ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ - Google Patents

ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
RU94019984A
RU94019984A RU94019984/04A RU94019984A RU94019984A RU 94019984 A RU94019984 A RU 94019984A RU 94019984/04 A RU94019984/04 A RU 94019984/04A RU 94019984 A RU94019984 A RU 94019984A RU 94019984 A RU94019984 A RU 94019984A
Authority
RU
Russia
Prior art keywords
alkyl
compounds
aryl
heteroaryl
interleukin
Prior art date
Application number
RU94019984/04A
Other languages
English (en)
Inventor
И.Долл Роланд
Us]
Дж.Шмидт Стэнли
У.Хойер Дентон
М.Росс Тина
М.Ринкер Джеймс
А.Этор Марк
Original Assignee
Стерлинг Уинтроп Инк. (US)
Стерлинг Уинтроп Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стерлинг Уинтроп Инк. (US), Стерлинг Уинтроп Инк. filed Critical Стерлинг Уинтроп Инк. (US)
Publication of RU94019984A publication Critical patent/RU94019984A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предлагаются соединения формулы и их фармацевтически приемлемые соли:где R- галоген, связанная через кислород уходящая группа, включающая простой ароматический эфир, сложный ароматический эфир, алкил сульфонат, арил сульфонат, алкил фосфонат, арил фофонат, алкил фосфат или арил фосфат; Rявляется OR, NH (CHR)- COOR, NH (CHR)CON (R)R, N (R)Rили NH (CHR)OH; представляет H или алкил; представляет H, замещенный или незамещенный арил, гетероарил или алкил; Rи Rпредставляют независимо H, низший алкил, арил, гетероарил, аралкил, гетероаралкил или низший циклоалкил; m = 1 - 6; n = 2 - 6, фармацевтические композиции, содержащие соединения, и способ ингибирования активности интерлейкин-1β протеазы у млекопитающих, использующий соединения и композиции.

Claims (1)

  1. Предлагаются соединения формулы и их фармацевтически приемлемые соли:
    Figure 00000001
    где R1 - галоген, связанная через кислород уходящая группа, включающая простой ароматический эфир, сложный ароматический эфир, алкил сульфонат, арил сульфонат, алкил фосфонат, арил фофонат, алкил фосфат или арил фосфат; R2 является OR5, NH (CHR5)m - COOR5, NH (CHR5)m CON (R5)R6, N (R5)R6 или NH (CHR5)nOH; представляет H или алкил; представляет H, замещенный или незамещенный арил, гетероарил или алкил; R5 и R6 представляют независимо H, низший алкил, арил, гетероарил, аралкил, гетероаралкил или низший циклоалкил; m = 1 - 6; n = 2 - 6, фармацевтические композиции, содержащие соединения, и способ ингибирования активности интерлейкин-1β протеазы у млекопитающих, использующий соединения и композиции.
RU94019984/04A 1993-06-08 1994-06-07 ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ RU94019984A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7391493A 1993-06-08 1993-06-08
US073914 1993-06-08

Publications (1)

Publication Number Publication Date
RU94019984A true RU94019984A (ru) 1997-04-10

Family

ID=22116553

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94019984/04A RU94019984A (ru) 1993-06-08 1994-06-07 ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ

Country Status (18)

Country Link
US (3) US6121266A (ru)
EP (1) EP0628550B1 (ru)
JP (1) JPH0769894A (ru)
KR (1) KR950000673A (ru)
AT (1) ATE163412T1 (ru)
AU (1) AU693786B2 (ru)
CA (1) CA2125359A1 (ru)
CZ (1) CZ140194A3 (ru)
DE (1) DE69408598T2 (ru)
DK (1) DK0628550T3 (ru)
ES (1) ES2114654T3 (ru)
FI (1) FI942693A (ru)
HU (1) HUT67413A (ru)
IL (1) IL109918A0 (ru)
NO (1) NO306061B1 (ru)
NZ (1) NZ260698A (ru)
RU (1) RU94019984A (ru)
SK (1) SK69794A3 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
WO1996030395A2 (en) * 1995-03-31 1996-10-03 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
GB9715640D0 (en) * 1997-07-24 1997-10-01 M J Highway Technology Limited Road repair material
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP1712239A3 (en) 2000-05-12 2007-08-22 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
CA2518227A1 (en) 2003-03-18 2004-09-30 Kowa Co., Ltd Water-soluble phenylpyridazine derivative and medicine containing the same
BRPI0417543A (pt) * 2003-12-12 2007-03-27 Wyeth Corp quinolinas úteis no tratamento de doença cardiovascular
EP2784090A1 (en) 2004-02-26 2014-10-01 Baylor Research Institute Compositions for the treatment of systemic onset juvenile idiopathic arthritis
EP1750689A1 (en) * 2004-05-15 2007-02-14 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
ES2543813T3 (es) 2004-11-02 2015-08-24 Northwestern University Compuestos de piridazina para el tratamiento de enfermedades inflamatorias
WO2007127375A2 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
CA2650711A1 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
KR102419136B1 (ko) 2017-06-15 2022-07-08 삼성전자주식회사 다채널 특징맵을 이용하는 영상 처리 장치 및 방법
JP2021531256A (ja) * 2018-07-09 2021-11-18 リーバー インスティチュート インコーポレイテッドLieber Institute, Inc. ＮａＶ１．８を阻害するピリダジン化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4590194A (en) * 1981-10-05 1986-05-20 Sterling Drug Inc. 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use
IE860511L (en) * 1985-03-01 1986-09-01 Alfa Farmaceutici Spa "Benzoyl urea derivatives having anti-tumor activity"
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
WO1991015577A1 (en) * 1990-04-04 1991-10-17 Black, Roy, A. INTERLEUKIN 1'beta' PROTEASE
DE69226820T2 (de) * 1991-06-21 1999-05-12 Merck & Co., Inc., Rahway, N.J. Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen
EP0628550B1 (en) 1993-06-08 1998-02-25 Sanofi Pyridazines as interleukin-1beta converting enzyme inhibitors

Also Published As

Publication number Publication date
US20040110725A1 (en) 2004-06-10
AU6455694A (en) 1994-12-15
NZ260698A (en) 1996-09-25
DE69408598T2 (de) 1998-09-17
EP0628550B1 (en) 1998-02-25
ES2114654T3 (es) 1998-06-01
NO942133D0 (no) 1994-06-08
FI942693A (fi) 1994-12-09
HUT67413A (en) 1995-04-28
EP0628550A2 (en) 1994-12-14
US6995261B2 (en) 2006-02-07
NO942133L (no) 1994-12-09
NO306061B1 (no) 1999-09-13
JPH0769894A (ja) 1995-03-14
KR950000673A (ko) 1995-01-03
DK0628550T3 (da) 1998-09-28
EP0628550A3 (en) 1995-01-18
US6624166B1 (en) 2003-09-23
US6121266A (en) 2000-09-19
IL109918A0 (en) 1994-10-07
SK69794A3 (en) 1995-02-08
AU693786B2 (en) 1998-07-09
ATE163412T1 (de) 1998-03-15
CZ140194A3 (en) 1995-01-18
CA2125359A1 (en) 1994-12-09
FI942693A0 (fi) 1994-06-08
DE69408598D1 (de) 1998-04-02
HU9401714D0 (en) 1994-09-28

Similar Documents

Publication Publication Date Title
RU94019984A (ru) ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ
DE69711391D1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
RU94046105A (ru) АНАЛОГИ γ -АМИНОМАСЛЯНОЙ КИСЛОТЫ И L-ГЛУТАМИНОВОЙ КИСЛОТЫ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
DE69515390D1 (de) Ureido-derivate von naphtalenphosphonsäure und verfahren zu ihrer herstellung
FI954016A0 (fi) Uudet yhdisteet
ATE256667T1 (de) Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen
HUP9903421A2 (hu) Foszfonsav és foszfinsavszármazékok alkalmazása NAALADáz inhibitor hatású gyógyszerkészítmények előállítására
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
AU6602594A (en) New phosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them
DE3854109D1 (de) Verfahren zur herstellung von chinolincarbonsäuren.
RU94036445A (ru) Производные оксадиазолкарбонамида, способ их получения, промежуточные соединения, способ их получения, гербицидная композиция, способ борьбы с сорняками
DE59712632D1 (de) Verfahren zur herstellung von 3-pyrrolin-2-carbonsäure-derivaten
DE3650106D1 (de) Verfahren zur Herstellung von Phosphonly-Hydroxyacyl-Prolinen.
ATE159517T1 (de) Verfahren zur herstellung von n-carbonylarylimine als zwischenprodukte in der synthese von therapeutisch aktiven taxol-derivaten
ATE236132T1 (de) Verfahren zur herstellung von 1,3-diaza- spiro(4.4)non-1-en-4-on derivaten und 1-cyano-1- acylaminocyclopentan zwischenprodukte
ATE189886T1 (de) Synthese von carbonsäurederivaten
DK601483A (da) Benzhydrylpiperazinderivater
ATE279434T1 (de) Neue (3,4,7,8,9,10) hexahydro-6, 10-dioxo-6h- pyridazino /1, 2-a/ /1, 2/ diazepin-1-carbonsäure-derivate, verfahren zu deren herstellung und deren verwendung zur herstellung pharmazeutischer wirkstoffe
EA199800470A1 (ru) Производные фосфоновой кислоты, обладающие ингибирующей активностью в отношении металлопептидаз
ATE25968T1 (de) 1,1-diphenylpropanol-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE263766T1 (de) Verfahren zur synthese von carbapenem- zwischenprodukten
TH25468EX (th) การยับยั้งฟอสฟาติดิลไอโนซิทอล 3-ไดเนสด้วยวอร์ทแมนนิล และอนาลอคของมัน
ATE226942T1 (de) Verfahren zur herstellung von 1,3-diaza- spiro(4.4)non-1-en-4-on derivaten und 1-cyano-1- acylamino-cyclopentan zwischenprodukten